It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint.
Regenxbio Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Regenxbio Inc is $716.60M. A total of 1.07 million shares were traded on the day, compared to an average of 574.92K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, RGNX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 0 SELLs from insiders. Insiders purchased 59,402 shares during that period but sold 0.
In the most recent transaction, Mills Kenneth T. sold 45,000 shares of RGNX for 15.18 per share on Jan 16. After the transaction, the President and CEO now owns 408,035 company shares. In a previous transaction on Jan 03, PAKOLA STEVE sold 17,237 shares at 17.39 per share. RGNX shares that Chief Medical Officer owns now total 107,192.
Among the insiders who sold shares, Mills Kenneth T. disposed of 45,000 shares on Dec 19 at a per-share price of $19.68. This resulted in the President and CEO holding 355,289 shares of RGNX after the transaction.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for RGNX in the last 3 months, the mean price target is $34.22 with high estimates of $52.00 and low estimates of $20.00. In terms of 52-week highs and lows, RGNX has a high of $25.32 and a low of $11.83.
As of this writing, RGNX has an earnings estimate of -$1.25 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.77 per share and a lower estimate of -$1.52. The company reported an EPS of -$1.66 in the last quarter, which was -20.30% lower than expectations of -$1.38.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RGNX’s latest balance sheet shows that the firm has $457.44M in Cash & Short Term Investments as of fiscal 2021. There were $86.68M in debt and $130.47M in liabilities at the time. Its Book Value Per Share was $8.25, while its Total Shareholder’s Equity was $764.30M.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RGNX is Buy with a score of 4.40.